Antigen-Specific Targeting of Tumours Across MHC Barriers

Time: 8:30 am
day: Day One


• Looking beyond peptide antigens in tumour therapy
• The advantages of targeting oligomorphic antigenpresenting molecules
• The advantages of adoptive cell therapies based on MR1- restricted TCRs specific for tumour-associated metabolites, and CD1c-restricted TCRs specific for a leukaemiaassociated lipid antigen